 NEW YORK, June 25, 2021 GLOBE NEWSWIRE -- Y-mAbs Therapeutics, Inc. the Company or Y-mAbs Nasdaq: YMAB a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the Committee for Orphan Medicinal Products COMP of the European Medicines Agency EMA has recommended the granting of orphan medicinal product designation OMPD in the European Union EU for 177Lu-omburtamab-DTPA for the treatment of medulloblastoma. The positive opinion from the EMAs COMP has been sent to the European Commission EC, which is expected to grant the orphan drug designation within 30 days. 